In June 2020, we also obtained the necessary approval for clinical studies. We are finally at the stage. However, an unexpected pitfall awaited here.
The venture company Organ Technologies, which was supposed to mass-produce and supply the "seeds" of hair follicles, failed to raise 2 billion yen in funding and was forced to suspend operations.
If it becomes a legal arrangement as it is, patents will be lost. So Mr. Tsuji took over the debt of Organ Corporation and completed the private liquidation.
Now, we are drawing up a blueprint to assemble a new management team, raise funds, conduct clinical research, and start free medical care using “seeds” from fiscal 2026.
“Clinical research for practical application requires the most money. Failure to raise funds is a direct hit from the corona crisis, but regenerative medicine for hair and teeth is not a life-threatening treatment in the first place, so clinical research In that case, it hurts that there is no public research funding.Actually, there is a high possibility that it will be the starting point for regenerative medicine research on various organs,” laments Mr. Tsuji.